New COVID-19 Vaccine Candidate to Address Virus Mutations
New York-based COVAXX announced on January 8, 2021, it has initiated preclinical work on a second vaccine candidate to address the latest mutations of the SARS-CoV-2 coronavirus responsible for COVID-19, and specifically the South African mutation.
The COVAXX multitope vaccine is being developed using high precision, commercially proven, and scalable synthetic peptide-based vaccine platform, designed to activate both B-cell and T-cell responses.
“We have been studying the new South African mutation and we believe it is a significant threat to public health," said COVAXX's CEO Mei Mei Hu, in a press statement. “As a result, we are not only testing UB-612 against these variants but have also begun early testing and design of a second vaccine candidate that addresses both the UK and the South African variant and the potential to be a single-dose vaccine for primary immunization.”